These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33506261)

  • 1. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
    Shufelt CL; Manson JE
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1245-1254. PubMed ID: 33506261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
    Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
    Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal.
    L'Hermite M
    Climacteric; 2017 Aug; 20(4):331-338. PubMed ID: 28301216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
    Cobin RH; Goodman NF;
    Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.
    Shufelt CL; Merz CN; Prentice RL; Pettinger MB; Rossouw JE; Aroda VR; Kaunitz AM; Lakshminarayan K; Martin LW; Phillips LS; Manson JE
    Menopause; 2014 Mar; 21(3):260-6. PubMed ID: 24045672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial.
    Casanova G; Spritzer PM
    Lipids Health Dis; 2012 Oct; 11():133. PubMed ID: 23046709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone therapy in menopause: An update on cardiovascular disease considerations.
    Hale GE; Shufelt CL
    Trends Cardiovasc Med; 2015 Aug; 25(6):540-9. PubMed ID: 26270318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
    L'Hermite M
    Climacteric; 2013 Aug; 16 Suppl 1():44-53. PubMed ID: 23848491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and benefit considerations for menopausal hormone therapy.
    Pickar JH; Archer DF; Kagan R; Pinkerton JV; Taylor HS
    Expert Opin Drug Saf; 2017 Aug; 16(8):941-954. PubMed ID: 28664754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
    Stephenson K; Neuenschwander PF; Kurdowska AK
    Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal delivery of bioidentical estrogen in menopausal hormone therapy: a clinical review.
    Files J; Kling JM
    Expert Opin Drug Deliv; 2020 Apr; 17(4):543-549. PubMed ID: 31795776
    [No Abstract]   [Full Text] [Related]  

  • 12. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
    Canonico M
    Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.
    Simon JA
    Climacteric; 2012 Apr; 15 Suppl 1():3-10. PubMed ID: 22432810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone.
    Mueck AO
    Climacteric; 2012 Apr; 15 Suppl 1():11-7. PubMed ID: 22432811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study.
    Miller VM; Taylor HS; Naftolin F; Manson JE; Gleason CE; Brinton EA; Kling JM; Cedars MI; Dowling NM; Kantarci K; Harman SM
    Climacteric; 2021 Apr; 24(2):139-145. PubMed ID: 32880220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.
    Simon JA; Laliberté F; Duh MS; Pilon D; Kahler KH; Nyirady J; Davis PJ; Lefebvre P
    Menopause; 2016 Jun; 23(6):600-10. PubMed ID: 26953655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women.
    Seed M; Sands RH; McLaren M; Kirk G; Darko D
    Fam Pract; 2000 Dec; 17(6):497-507. PubMed ID: 11120722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of oestrogens and progestogens.
    Lauritzen C
    Maturitas; 1990 Sep; 12(3):199-214. PubMed ID: 2215269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.